Hereditary Cancer in Clinical PracticeMcKinley JM, Weideman PC, Jenkins MA, Friedlander ML, Hopper JL, McLachlan SA, et al. Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. Hered Cancer Clin Pract 2007;5:161-3.McKinley JM, Weideman PC, Jenkins MA, Friedlander ML, Hopper...
the heterogeneity between estimates was high (I2 = 66%). A leave-one-out analysis identified three outliers (Supplementary TableS7): a UK family-based retrospective cohort study (P = 0.010) [16], the IMPACT screening trial (P = 0.013) [20], and a Dutch kin...
ImportanceHalf of all carriers of inherited cancer-predisposing variants inBRCA1andBRCA2are male, but the implications for their health are underrecognized compared to female individuals. Germline variants inBRCA1andBRCA2(also known as pathogenic or likely pathogenic variants, referred to here asBRCA1...
BRCA2is located on chromosome 13 and accounts for approximately 35% of familial breast cancer, less than BRCA1. It is thought that BRCA2 contributes fewer cases of early-onset breast cancer than does BRCA1. BRCA2 carriers are at risk of developing other cancers: prostate, bladder, pancreatic,...
Bancroft EK, Raghallaigh HN, Page EC, Eeles RA. Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. Curr Genet Med Rep. 2021;9(4):47-58. doi: 10.1007/s40142-021-00202-5. Epub 2021 Oct 8. PMID: 34790437; PMCID: PMC8585808....
For those individ- uals who have a BRCA1 or BRCA2 mutation, several screening and From the 1Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan; 2Cancer Control Program, Fox Chase Cancer Center, Cheltenham, Pennsylvania; and 3Center for Molecular Medicine and...
In healthy women with a BRCA2 mutation, the lifetime risk of developing BC and ovarian cancer (OC) ranges from 38.0% to 84.0% and 16.5% to 27.0%, respectively [2, 22,23,24]. Consequently, it is essential to conduct regular surveillance for BC and OC. Screening for BC in healthy wome...
"These data will help to optimize medical care in male BRCA1 and BRCA2 PV carriers," Dr. Ottini said. "In particular, screening and surveillance programs in men with BRCA1 and BRCA2 PVs should be tailored in light of these gene-specific cancer phenotype differences." ...
Prostate cancer diagnosis,n 16 26 Median age at prostate cancer diagnosis, yr (interquartile range) 66.0 (61.9–71.7) 71.4 (62.8–77.5) Diagnostic modality, n (%) Screening 11 (69) 14 (54) Clinical symptoms 3 (19) 7 (27) Missing data 2 (13) 5 (19) Median PSA at diagnosis, ng...
More particularly, the invention relates to the discovery of novel BRCA1/BCRA2 mutations or polymorphisms associated with breast cancer and with the development of a BRCA1/BCRA2 mutation screening panel. BACKGROUND African-American (AA) women under 50 years of age have the highest rate of new ...